Institution scientifique

Lundbeck (Denmark)

Copenhagen · DK · company

4321Publications signalées

492890Citations signalées

12Thèmes principaux

Principaux domaines

Treatment of Major DepressionNeuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on BehaviorSchizophrenia research and treatmentReceptor Mechanisms and SignalingAlzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchTryptophan and brain disordersParkinson's Disease Mechanisms and TreatmentsAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesMigraine and Headache StudiesBipolar Disorder and Treatment

Évolution annuelle

199632

199739

199848

200043

200146

200244

200364

200480

200572

200692

200792

200892

200997

2010126

2011139

2012133

2013172

2014195

2015176

2016200

2017159

2018135

2019153

2020130

2021173

2022203

2023193

2024143

2025130

2026110

Publications récentes

Accès ouvert 2026 articleOpenAlex

Real-world adherence, healthcare resource utilization, and costs following a transition to aripiprazole once every 2 months among patients diagnosed with bipolar I disorder in the United States

Soma S. Nag, Annette Urganus, Karimah S. Bell Lynum, Norman Atkins et autres

0 citationsFrontiers in Psychiatry

Accès ouvert 2026 articleOpenAlex

Real-world adherence and healthcare resource utilization following transition to aripiprazole once-every-2-months from oral or once-monthly aripiprazole among patients diagnosed with schizophrenia in the United States

Kristine Harrsen, Murat Yildirim, Clodagh Beckham, Karimah S. Bell Lynum et autres

0 citationsCurrent Medical Research and Opinion

Accès ouvert 2026 articleOpenAlex

Neurobiological correlates of longitudinal grey matter volume changes in preclinical Alzheimer’s disease

Wiesje Pelkmans, Raffaele Cacciaglia, Michalis Kassinopoulos, Oriol Grau‐Rivera et autres

0 citationsMolecular Neurodegeneration

Accès ouvert 2026 articleOpenAlex

Multiple system atrophy-derived α-synuclein fibrils are more potent and display oligodendrocyte cell tropism compared to Parkinson's disease-derived fibrils

Anne-Line Strange Laursen, Katarina Willén, Alexis Fenyi, Christiane Volbracht et autres

0 citationsNeurobiology of Disease

Accès ouvert 2026 preprintOpenAlex

GESTURE: unsupervised genotype-specific behavioral phenotyping in rodents via graph-based representation learning

Renxiang Qiu, Sadaf Farkhani, Taha Al Muhammadee Janjua, Ece Canko et autres

0 citationsbioRxiv (Cold Spring Harbor Laboratory)

Accès ouvert 2026 articleOpenAlex

The association of schizophrenia polygenic scores with continuously-hospitalized, treatment-resistant schizophrenia

Urmi Das, James J. Crowley, Robert Karlsson, Yi Lu et autres

0 citationsMolecular Psychiatry

2026 articleOpenAlex

The evolving role of investigative toxicology in drug safety: Insights from a 2025 Industry-Wide Survey

Jean Pierre Valentin, Klaus A. Rytved, Lilou Babinet, Mario Beilmann et autres

0 citationsJournal of Pharmacological and Toxicological Methods

Accès ouvert 2026 articleOpenAlex

Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence

Roger S. McIntyre, Masaki Kato, Michael E. Thase, François Therrien et autres

0 citationsCNS Drugs

2026 articleOpenAlex

From Uncertainty to Resilience: How ESG Scores Moderated Market Capitalization Shocks amid the Russian Invasion of Ukraine

Kristjan Jespersen, Katryn Pasaribu, Andreas Gonzalez Elsgaard, Jonas Aastrup Nielsen

0 citationsThe Journal of Impact and ESG Investing

2026 articleOpenAlex

Effects of Brexpiprazole on Functioning in Patients With Schizophrenia Who Have Hostility and Agitation Symptoms

Leslie Citrome, Anja Farovik, Anton M. Palma, Murat Yildirim

0 citationsThe Journal of Clinical Psychiatry

Accès ouvert 2026 datasetOpenAlex

Available IPD datapackage for study 'A Parallel Group, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing an Acute Attack of Migraine'

Lundbeck

0 citationsVivli

Accès ouvert 2026 datasetOpenAlex

Available IPD datapackage for study 'A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients With Chronic Migraine'

Lundbeck

0 citationsVivli

Identifiant ROR

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.